Format

Send to

Choose Destination
Mol Biosyst. 2016 Jun 21;12(7):2047-55. doi: 10.1039/c5mb00699f.

Antibodies as stratagems against cancer.

Author information

1
Computational Biology & Medicine Group, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, Athens 11527, Greece. dvlachakis@bioacademy.gr and Department of Informatics and Telecommunications, National and Kapodistrian University of Athens, University Campus, Athens, 15784, Greece.
2
Computational Biology & Medicine Group, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, Athens 11527, Greece. dvlachakis@bioacademy.gr.
3
Computational Biology & Medicine Group, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, Athens 11527, Greece. dvlachakis@bioacademy.gr and Computer Engineering and Informatics Department, School of Engineering, University of Patras, 26500 Patras, Greece.

Abstract

Antibodies have been in the frontline of anticancer research during the last few decades, since a number of different ways have been discovered to utilize them as parts or main components of anticancer drugs. Antibodies are used as the only component of some anticancer drugs, but they can also be conjugated with a variety of substances. Antibody engineering methods such as humanization, chimerization and Fc engineering are applied in order to modify their properties according to the requirements of anticancer drug application. Given the continuous advances in biology and informatics, the role of antibodies in anticancer treatment is expected to be prominent.

PMID:
26738941
DOI:
10.1039/c5mb00699f
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Royal Society of Chemistry
Loading ...
Support Center